BioNTech SE Sponsored ADR $BNTX Shares Sold by Baillie Gifford & Co.

Key Points

• Baillie Gifford & Co. cut its BioNTech stake by 84.2% in Q4, selling 6,634,492 shares and retaining 1,244,867 shares worth about $118.5 million (≈0.55% of the company).
• BioNTech reported a Q that included ($0.39) EPS"Moderate Buy" rating with a $133.13 target.

Baillie Gifford & Co. decreased its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 84.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,244,867 shares of the company's stock after selling 6,634,492 shares during the period. Baillie Gifford & Co. owned approximately 0.55% of BioNTech worth $118,511,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Banque Pictet & Cie SA boosted its position in shares of BioNTech by 12.6% during the 4th quarter. Banque Pictet & Cie SA now owns 21,735 shares of the company's stock worth $2,069,000 after purchasing an additional 2,424 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of BioNTech by 1,664.6% during the 4th quarter. SG Americas Securities LLC now owns 365,333 shares of the company's stock worth $34,780,000 after purchasing an additional 344,630 shares in the last quarter. Arlington Capital Management Inc. purchased a new stake in shares of BioNTech during the 4th quarter worth $248,000. Hudson Bay Capital Management LP boosted its position in shares of BioNTech by 36.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 205,004 shares of the company's stock worth $20,217,000 after purchasing an additional 55,004 shares in the last quarter. Finally, Krensavage Asset Management LLC boosted its position in shares of BioNTech by 8.2% during the 3rd quarter. Krensavage Asset Management LLC now owns 79,366 shares of the company's stock worth $7,827,000 after purchasing an additional 5,984 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Up 1.3%

Shares of NASDAQ:BNTX opened at $96.70 on Tuesday. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $24.45 billion, a P/E ratio of -18.45 and a beta of 1.58. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The stock's fifty day simple moving average is $98.57 and its 200-day simple moving average is $101.04.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The company had revenue of $1.06 billion for the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. As a group, equities research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Jefferies Financial Group restated a "buy" rating on shares of BioNTech in a research report on Wednesday, March 25th. Morgan Stanley boosted their target price on shares of BioNTech from $125.00 to $126.00 and gave the stock an "overweight" rating in a research report on Friday. Canaccord Genuity Group reissued a "buy" rating and issued a $171.00 target price on shares of BioNTech in a report on Wednesday, March 11th. BMO Capital Markets lowered their target price on BioNTech from $143.00 to $128.00 and set an "outperform" rating on the stock in a report on Wednesday, March 11th. Finally, The Goldman Sachs Group reissued a "buy" rating on shares of BioNTech in a report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $133.13.

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.